COREE Group, an affiliate of Hanmi Science,
will push its own platform, "life intervention", into the US market
with the ability to improve living habits and predict diseases. Its goal is to
obtain a license for the medical software (SaMD•Software as Medical Device)
from the Food and Drug Administration (FDA).
It is undeniable that it will take several
years to apply for FDA license. Currently, COREE Group has reached close
cooperation with local hospitals in China and Italy and is conducting clinical
researches. In order to achieve more accurate and lasting development of
related platforms, the artificial intelligence (AI) technology is also used.
On November 18, Sang-tae Park, the US legal
representative of the COREE Group, gave an interview to news1 at the Sixth
China Healthcare Summit in Shanghai, China, and unveiled the above plan.
Sang-tae Park, the US legal representative,
disclosed: "life intervention" is a customized platform that provides
a wide range of personal health, life, and treatment services, with plans to
enter the US market.
Currently, COREE Group and Peking Union
Medical College Hospital are cooperating on clinical researches. A follow-up
study of local pregnant women with gestational diabetes of using the customized
health management showed that some of their blood glucose levels were under
control and that there was a positive reaction. In Italy, the Roman Catholic
University and the Gemelli Hospital set up and operated the Biobank,
"Mother and Child and Beyond".
Through exchanges and cooperation with
these institutions, the COREE Group plans to expand the Biobank project, which
accumulates a variety of human information. The Biobank is a human resource
bank that collects, saves and sells information of human derivatives such as
cells, tissues and DNA. If we can accumulate the information on a large scale,
and master AI technology to extract core information, we can take a step
forward in precision medicine.
COREE hopes that the US at the accumulated
data and technology capabilities in China and Italy will be the cornerstone of
its future forays into the US Market. The US legal representative also
mentioned: "the Group is considering a plan to come up with a THERAPEUTICS
Center in the western United States, which focuses on the future and
accelerates technology development."
Meanwhile, the global market for
intelligent health care, including Life Intervention, is growing dramatically
every year. Statista, a market-research institute, predicts that the $60.8
billion global market for intelligent health care will grow to $233.3 billion
by 2020.
Intelligent health care is a cross-industry
chain involving health, medical, information, machines, platforms and so on,
which provides a medical service combining of biotechnology (BT) and
information technology (IT).
